Breztri Active Ingredients
Breztri Aerosphere contains three active medications: budesonide (an inhaled corticosteroid), glycopyrrolate (a long-acting muscarinic antagonist/anticholinergic), and formoterol fumarate (a long-acting beta2-agonist). 1
Specific Drug Components
The three medications in Breztri represent distinct therapeutic classes that work through different mechanisms:
Budesonide: An inhaled corticosteroid (ICS) that provides anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators involved in airway inflammation 1
Glycopyrrolate: A long-acting antimuscarinic antagonist (LAMA), also called an anticholinergic, that blocks M3 muscarinic receptors on airway smooth muscle to produce bronchodilation 1
Formoterol fumarate: A long-acting beta2-adrenergic agonist (LABA) with rapid onset that relaxes bronchial smooth muscle through beta2-receptor activation, providing bronchodilation 1
Dosing Information
Each actuation delivers 160 mcg budesonide, 9.0 mcg glycopyrrolate (equivalent to 7.2 mcg glycopyrronium), and 4.8 mcg formoterol fumarate (equivalent to 4.1 mcg formoterol) from the actuator 1. The medication is formulated as a pressurized metered-dose inhaler using HFA-134a propellant with porous particle technology.
This triple combination therapy addresses multiple pathophysiologic mechanisms in COPD and asthma by simultaneously targeting inflammation (budesonide), two different bronchodilator pathways (glycopyrrolate and formoterol), and has been shown to improve lung function, reduce hyperinflation, and decrease exacerbations 2.